Cytochrome P450 eicosanoids in hypertension and renal disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 1, 2015, Pages 37-46

  Fan, Fan ^a   Muroya, Yoshikazu ^a   Roman, Richard J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

20 HETE; Acute kidney injury; Chronic kidney disease; Epoxyeicosatrienoic acids; Hypertension and diabetic nephropathy; Polycystic kidney disease

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATASE; AMIODARONE; ARACHIDONIC ACID; BRADYKININ; CALCIUM; CARBAMAZEPINE; CARBON MONOXIDE; CYTOCHROME P450; CYTOCHROME P450 4A11; EPITHELIAL SODIUM CHANNEL; EPOXYICOSATRIENOIC ACID; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; GEMFIBROZIL; GLITAZONE DERIVATIVE; IBUPROFEN; ICOSANOID; MONTELUKAST; NICARDIPINE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; TERFENADINE; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG; WARFARIN; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; ARACHIDONIC ACID DERIVATIVE; CYP4A11 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; HYDROXYICOSATETRAENOIC ACID; SODIUM;

ACUTE KIDNEY FAILURE; APICAL MEMBRANE; BLOOD VESSEL TONE; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GENETIC DISORDER; GLOMERULOPATHY; GLOMERULUS CAPILLARY; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY PROXIMAL TUBULE; MICROCIRCULATION; NEPHRITIS; OXIDATIVE STRESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM TRANSPORT; URINARY EXCRETION; VASCULAR SMOOTH MUSCLE; WATER ABSORPTION; BLOOD VESSEL; GENETICS; KIDNEY TUBULE; METABOLISM; PATHOPHYSIOLOGY;

ARACHIDONIC ACIDS; BLOOD VESSELS; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY DISEASES; KIDNEY TUBULES; SODIUM;

EID: 84918822626     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000088     Document Type: Review

References (82)

1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
2. Fava C, Ricci M, Melander O, et al. Hypertension, cardiovascu lar risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012; 98:75-85.
3. Ward NC, Tsai IJ, Barden A, e t al. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J Hypertens 2014; 32:1495-1502
4. Liang JQ, Yan MR, Yang L, et al. Association of a CYP4A11 polymorphism and hypertension in the Mongolian and Han populations of China. Genet Mol Res 2014; 13:508-517.
5. Sun D, Cuevas AJ, Gotlinger K, et al. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. Am J Physiol Heart Circ Physiol 2014; 306:H1146-H1153.
6. Kujal P, Certikova Chabova V, Skaroupkova P, et al. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol 2014; 41:227-237.
7. Capdevila J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens 2013; 22:163-169.
8. Wang WH, Zhang C, Lin DH, et al. Cyp2c44 epoxygenase in the collecting duct is essential for the high K intake-induced antihypertensive effect. Am J Physiol Renal Physiol 2014; 307:F453-F460.
9. Eid S, Maalouf R, Jaffa AA, et al. 20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway. PLoS One 2013; 8:e70029. Recent study implicating a role of 20-HETE in diabetic nephropathy.
10. Chen G, Xu R, Wang Y, et al. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Endocrinol Metab 2012; 303:E563-E575.
11. Wu CC, Gupta T, Garcia V, et al. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 2014; 22:1-12.
12. Regner KR, Roman RJ. Role of medullary blood flow in the pathogenesis of renal ischemia-reperfusion injury. Curr Opin Nephrol Hypertens 2012; 21:33-38.
13. Klawitter J, Klawitter J, McFann K, et al. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res 2013; 55:1139-1149.
14. Akbulut T, Regner KR, Roman RJ, et al. 20-HETE activates the Raf/MEK /ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism. Am J Physiol Renal Physiol 2009; 297:F662-F670.
15. Park F,Sweeney WE,Jia G,et al. 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease, J Am Soc Nephrol, 2008, 19, 1929-1939.
16. Park F, Sweeney WE, Jia G, et al. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Am J Physiol Renal Physiol 2009; 296:F575-F582.
17. Fan F, Sun CW, Maier KG, et al. 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS One 2013; 8:e82482.
18. Williams JM, Murphy S, Burke M, et al. 20-HETE: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 2010; 56:336-344.
19. Gebremedhin D, Lange AR, Narayanan J, et al. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2 current. J Physiol 1998; 507:771-781.
20. Basora N, Boulay G, Bilodeau L, et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells. J Biol Chem 2003; 278:31709-31716.
21. Brayden JE, Earley S, Nelson MT, et al. Transient receptor potential (TRP) channels, vascular ton e and autoregulation of cerebral blood flow. Clin Exp Pharmacol Physiol 2008; 35:1116-1120.
22. Gebremedhin D, Lange AR, Lowry TF, et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 2000; 87:60-65.
23. Ge Y, Murphy SR, Lu Y, et al. Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles. Prostaglandins Other Lipid Mediat 2013; 102 - 103:42-48. A study showing the essential role of 20-HETE in myogenic and TGF responses in the Af-art.
24. Williams JM, Sarkis A, Lopez B, et al. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 2007; 49:687-694.
25. Ren Y, D'Ambrosio MA, Garvin JL, et al. Mecha nism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am J Physiol Renal Physiol 2014; 307:F533-F538.
26. Ge Y, Murphy SR, Fan F, et al. Role of 20-HETE in the impaired myogenic and TGF responses of the Af-Art of Dahl salt-sensitive rats. Am J Physiol Renal Physiol 2014; 307:F509-F515.
27. Williams JM, Fan F, Murphy S, et al. Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2012; 302:R1209-R1218.
28. Fan F, Ge Y, Murphy S, et al. CYP4A1 transgenic rats generated using Sleeping Beauty transposon system restores the impaired myogenic responses in the afferent arteriole of Dahl S rats. Hypert ension 2013; 62:A39 (abstract
29. Benter IF, Yousif MH, Canatan H, et al. Inhibition of Ca2/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates t he development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol Res 2005; 52:252-257.
30. Luo P, Zhou Y, Chang HH, et al. Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. Am J Physiol Renal Physiol 2009; 296:F556-F563.
31. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat 2013; 104 -105:2-7. An excellent recent review on the renal vascular actions of EETs.
32. Sudhahar V, Shaw S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem 2010; 17:1181-1190.
33. Hye Khan MA, Pavlov TS, Christain SV, et al. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond) 2014; 127:463-474.
34. Lee CR, Imig JD, Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertensioninduced renal injury in mice. FASEB J 2010; 24:3770-3781.
35. Manhiani M, Quigley JE, Knight SF, et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physi ol Renal Physiol 2009; 297:F740-F748.
36. Sinal CJ,Miyata M,Tohkin M,et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation, J Biol Chem 2000, 275, 40504-40510.
37. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, et al. Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am J Physiol Regul Integr Comp Physiol 2004; 287:R58-R68.
38. Fernandez MM, Gonzalez D, Williams JM, et al. Inhibitors of 20-hydroxyeicosatetraenoic acid (20-HETE) formation attenuate the natriuretic effect of dopamine. Eur J Pharmacol 2012; 686:97-103.
39. Yu M, Lopez B, Dos Santos EA, et al. Effects of 20-HETE on Na transport and Na-K-ATPase activity in the thick ascending loop of Henle. Am J Physiol Regul Integr Comp Physiol 2007; 292:R2400-R2405.
40. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2)-induced inhibition of apical K channels in the TAL. Am J Physiol 1996; 271:C103-C111.
41. Zhang MZ, Wang Y, Yao B, et al. Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney. Am J Ph ysiol Renal Physiol 2013; 305:F1680-F1686.
42. Wei Y, Lin DH, Kemp R, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 2004; 124:719-727.
43. Sun P, Antoun J, Lin DH, et al. Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hyperte nsion 2012; 59:339-347.
44. Pavlov TS, Ilatovskaya DV, Levchenko V, et al. Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol 2011; 301:F672-F681.
45. Singh H, Cheng J, Deng H, et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androg en-induced hypertension. Hypertension 2007; 50:123-129.
46. Yanes LL, Lima R, Moulana M, et al. Postmenopausal hypertension: role of 20-HETE. Am J Physiol Regul Integr Comp Physiol 2011; 300:R1543-R1548.
47. Quigley R, Chakravarty S, Zhao X, et al. Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. Nephron Physiol 2009; 113:23-28.
48. Holla VR, Adas F, Imig JD, et al. Alterations in the regulation of androgensensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001; 98:5211-5216.
49. Wu CC, Mei S, Cheng J, et al. Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol 2013; 24:1288-1296.
50. Liu X, Zhao Y, Wang L, et al. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int 2009; 75:1288-1296.
51. Makita K, Takahashi K, Karara A, et al. Experimental and/or geneticall y controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414-2420.
52. Gainer JV, Bellamine A, Dawson EP, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111:63-69.
53. Gainer JV, Lipkowitz MS, Yu C, et al. Association of a CYP4A11 variant and blood pressure in black men. J Am Soc Nephrol 2008; 19:1606-1612.
54. Laffer CL, Gainer JV, Waterman MR, et al. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 2008; 51:767-772.
55. Mayer B, Lieb W, Gotz A, et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005; 46:766-771.
56. Mayer B, Lieb W, Gotz A, et al. Association of a functional polymorphismin the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006; 24:1965-1970.
57. Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007; 30:74-81.
58. Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 2008; 51:1393-1398.
59. Fu Z, Nakayama T, Sato N, et al. A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am J Hypertens 2008; 21:1216-1223.
60. Liu H, Zhao Y, Nie D, et al. Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol 2008; 19:714-721.
61. Fava C, Montagnana M, Almgren P, et al. The V433M variant of the CYP4F2 is associated with ischem ic stroke in male Swedes beyond its effect on blood pressure. Hypertension 2008; 52:373-380.
62. Ding H, Cui G, Zhang L, et al. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics 2010; 20:187-194.
63. Liu H, Zhao YY, Gong W, et al. Correlation analysis and identification of G421C in regulatory region of CYP4F2 gene with essential hypertension. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006; 28:143-147.
64. Dreisbach AW, Smith SV, Kyle PB, et al. Urinary CYP eicosanoid excretion correlates with glomerular filtration i n African-Americans with chronic kidney disease. Prostaglandins Other Lipid Mediat 2014; pii: S1098-8823(14)00033-1. doi: 10.1016/j.prostaglandins.2014.08.002. [Epub ahead of print] The first study showing 20-HETE excretion is associated with the progression of renal injury in humans.
65. Capdevila JH, Pidkovka N, Mei S, et al. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure respo nses to increased dietary salt. J Biol Chem 2014; 289:4377-4386.
66. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epit helial sodium channel. J Clin Invest 2006; 116:1696-1702.
67. Imig JD,Hammock B D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009; 8:794-805.
68. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348:57-61.
69. Dahly-Vernon AJ, Sharma M, McCarthy ET, et al. Transforming growth factorbeta, 20-HETE interaction, and glomerular inj ury in Dahl salt-sensitive rats. Hypertension 2005; 45:643-648.
70. Williams JM, Sharma M, Anjaiahh S, et al. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerul ar protein permeability barrier. Am J Physiol Renal Physiol 2007; 293:F501-F505.
71. Eid S, Abou-Kheir W, Sabra R, et al. Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy. J Biol Regul Homeost Agents 2013; 27:693-703.
72. Eid AA, Gorin Y, Fagg BM, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009; 58:1201-1211.
73. Chen G, Wang P, Zhao G, et al. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid M ediat 2011; 96:63-71.
74. Regner KR, Zuk A, Van Why SK, et al. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int 2009; 75:511-517.
75. Hoff U, Lukitsch I, Chaykovska L, et al. Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int 2011; 79:57-65.
76. . Roman RJ, Akbulut T, Park F, et al. 20-HETE in acute kidney injury. Kidney Int 2011; 79:10-13.
77. Liu Y, Webb HK, Fukushima H, et al. Attenuation of cisplatin-induced ren al injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling. J Pharmacol Exp Ther 2012; 341:725-734.
78. Jarrar YB,Cha EY,Seo KA,et al. Determination of majo r UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation, J Lipid Resk 2014;55:2334-2342 , [Epub ahead of print]
79. Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome p450-mediated cardiovascular drug interactions. Dis Mon 2010; 56:163-179.
80. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278:165-188.
81. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77:341-352.
82. Knights KM, Rowland A, Miners JO. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 2013; 76:587-602.